ST8Sia6 expression on tumors inhibits the immune response

Project: Research project

Project Details


Project Narrative The recently discovered checkpoint inhibitors for cancer immunotherapy that target T cell activation through blockage of PD1/PDL1 or CTLA4 have had amazing success in a subset of cancers but poor success in other cancer types. Thus, additional targets for therapeutic intervention are needed that boost the immune response and, in particular, ones that target the innate immune system. The focus of this proposal is to understand how expression of ST8Sia6 accelerates tumor growth through modulation of the immune response through Siglec- E, and to determine if ST8Sia6 downregulation on tumors renders them more susceptible to immune attack.
Effective start/end date12/1/1911/30/22


  • National Cancer Institute: $359,463.00


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.